| answer text |
<p>The Department meets regularly with the National Institute for Health and Care
Excellence (NICE) to discuss a range of issues, including access to medicines. The
NICE has recommended Enhertu, also known as trastuzumab deruxtecan and made by Daiichi
Sankyo, for use through the Cancer Drugs Fund, for the treatment of HER2-positive
metastatic or unresectable breast cancer. It is available to eligible National Health
Service patients in England, in line with the NICE’s recommendations.</p><p>The NICE
is currently evaluating Enhertu for the treatment of HER2-low metastatic or unresectable
breast cancer. Following negotiations between NHS England and the company, which concluded
without a commercial agreement to make it available at a cost-effective price for
the NHS, the NICE published final draft guidance on 5 March 2024, that does not recommend
it as an option for this indication. The NICE remains open to further discussions
with NHS England and the company, and currently expects to publish final guidance
on 15 May 2024.</p>
|
|
